deflazacort

FDA Approves Drug to Treat Duchenne Muscular Dystrophy, but Congress Has Problems
Muscular dystrophy drug launch halts after pricing concernsMarathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.